IBO
AMEX · Pharmaceuticals
Impact Biomedical Inc
$0.63
-0.01 (-1.24%)
Financial Highlights (FY 2026)
Revenue
104.6K
Net Income
-39,253,882
Gross Margin
84.4%
Profit Margin
-36,993.8%
Rev Growth
—
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.4% | 43.8% | 43.8% | 43.8% |
| Operating Margin | -13,381.2% | 16.3% | 15.1% | 14.9% |
| Profit Margin | -36,993.8% | 12.5% | 12.2% | 10.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 104.6K | 2.01M | 2.09M | 2.10M |
| Gross Profit | 88.3K | 880.9K | 914.6K | 918.2K |
| Operating Income | -13,999,597 | 328.7K | 316.6K | 312.7K |
| Net Income | -39,253,882 | 252.5K | 255.6K | 224.6K |
| Gross Margin | 84.4% | 43.8% | 43.8% | 43.8% |
| Operating Margin | -13,381.2% | 16.3% | 15.1% | 14.9% |
| Profit Margin | -36,993.8% | 12.5% | 12.2% | 10.7% |
| Rev Growth | — | +12.9% | +6.5% | +8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.54M | 1.92M | 2.21M | 2.19M |
| Total Equity | 31.26M | 3.68M | 3.82M | 3.64M |
| D/E Ratio | 0.05 | 0.52 | 0.58 | 0.60 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -10,399,349 | 413.4K | 402.4K | 414.7K |
| Free Cash Flow | — | 302.8K | 206.2K | 229.1K |